Francisco‐Javier Gamo

This study shows that CHIR-124, a human Chk1 inhibitor, is active against Plasmodium falciparum through dual inhibition of PfArk1 and hemozoin formation, suggesting polypharmacology as a strategy for antimalarial drugs.

This paper identifies targets of dual-active antimalarials by evolving resistance to nine compounds and validates them using CRISPR and molecular docking.

This paper develops a chemogenomic platform using Plasmodium berghei artificial chromosomes to identify antimalarial drug targets through barcode sequencing and validation in Plasmodium falciparum.

The paper identifies antimalarial compounds that inhibit ApiAP2 proteins in Plasmodium falciparum by screening small molecules against the AP2-EXP domain and validating their effects on parasite gene regulation and growth.

The paper analyzes G6PD variant distribution in sub-Saharan Africa and highlights potential risks of using chloroquine/hydroxychloroquine for COVID-19 due to G6PD deficiency.

This study characterizes ADME gene variation in sub-Saharan African populations, identifying novel variants and highlighting the need for tailored pharmacogenomic approaches.

Whole genome sequencing reveals how Plasmodium falciparum evolves resistance to diverse compounds and identifies new antimalarial drug targets.